Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| KPV | Immune & Inflammation | Not approved | None established | — | — | C | View |
| Larazotide | Immune & Inflammation | Investigational | Phase 2b celiac trial (NCT01396213): 0.5, 1 or 2 mg three times daily for 12 weeks; phase 3 (NCT03569007): 0.25 or 0.5 mg three times daily | Oral capsule | — | B | View |
| LL-37 | Immune & Inflammation | Not approved | None established | Topical application to ulcers (solution or cream) and intratumoral injection in the published human trials | — | B | View |
| PEA | Immune & Inflammation | Not approved | None established | Oral in the human trials reviewed (micronized, ultramicronized and water-dispersible formulations), with topical formulations in dermatology studies | — | A | View |
| PNC-27 | Immune & Inflammation | Not approved | None established | — | — | D | View |
| Thymosin Alpha-1 | Immune & Inflammation | Approved outside the US | None established | Subcutaneous injection in the published trials | — | B | View |
| Thymulin | Immune & Inflammation | Not approved | None established | — | Not located in the sources reviewed for any species. | C | View |
| VIP | Immune & Inflammation | Investigational | Intravenous aviptadil 50, 100 and 150 pmol/kg/hour on three successive days in a US phase 2b/3 trial, and infusions targeting 600, 1200 and 1800 pmol/kg on days 1 to 3 in TESICO; inhaled aviptadil 2 mL of a 100 microgram/mL solution per day in a COVID-19 trial; a single inhaled 100 microgram dose in pulmonary hypertension | Intravenous infusion and inhalation (nebulizer) in the human trials | A review of VIP in cardiopulmonary disease states that clinical application of VIP has been limited by, among other reasons, its short plasma half-life and the difficulty of administration routes; that review does not give a numeric value and none is quoted here | A | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.